Loading
Insulet Corp Stock: price and insider trades · United States
1 insider bought €139k of shares over the last 90 days, the latest by McEvoy Ashley, filed 24 Aug 2026.
Insulet Corp: what insiders have been doing
Every trade that managers of Insulet Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Bedford, United States. It was founded in 2000. Between 18 October 2025 and 18 October 2026, 16 insiders published 38 filings.
Purchases and sales both appear in the filings: 4 purchases (3 insiders, €1.7M) and 2 sales (2 insiders, €514k). Taken together, the purchases exceed the sales by €1.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €874k by McEvoy Ashley, published on 23 February 2026. Among those who bought: 2 senior executives and 1 chief executive.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 24 August 2026, 55 days ago. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,458 companies, median 22 filings), a count of 38 filings is above the norm. Over the whole record (from 2016), the tally stands at 8 purchases and 39 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at 247.1 m USD.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
295
Thresholds
n/a
Buy Volume
€4M
8 ops. · all time
Sell Volume
€22M
39 ops. · all time
Who traded when
BuySaleLuciana Borio3 sales
Ashley McEvoy2 buys
Eric Benjamin2 sales
Wayne A.I. Frederick2 sales
Lauren Budden1 sale
Manea Dan1 sale
+3 other insiders
Since the insiders bought
- -1.4%Entry US$143.05 · Close 16 Oct 2026 US$141.10
- -42.2%Entry US$246.61 · Close at T+90 US$142.65
- -18.3%Entry US$294.20 · Close at T+90 US$240.38
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Insulet Corp Buy (bullish), based on 23 analysts. Average price target: US$167.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,652 of 23,474 companies
58.1
score / 100
Value42
Quality74
FCF yld3.6%
Earn yld2.5%
EV/EBITDA21.9x
ROE26%
Gross mgn72%
Net mgn9.1%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$141.10
Analyst consensus
23 analystsBuy
US$143.00Target US$167.17(+18%)US$215.00
Income statement
RevenueUS$2.7B
Gross profitUS$1.9B72% margin
EBITDAUS$489.3M18% margin
Net incomeUS$247.1M12.3% margin
Valuation
PER (trailing)26.4x
PER (forward)18.3x
P/Book6.9x
Beta1.10
Balance sheet & cash
Market capUS$9.8B
Total debtUS$949.2M
Free Cash FlowUS$349.9M
Debt / Equity67%
Profitability & ownership
ROE26.0%
ROA9.7%
% insiders0.3%
% institutions107.0%
Last declaration on 5 October 2026
Declarations295 total
1,882 shares@ US$130.790.0026% mcap100.0% of flowCommon StockSEC:0001145197-26-000186:0
178 shares@ US$130.470.0002% mcap38.7% of flowCommon StockSEC:0001145197-26-000183:0
141 shares@ US$130.470.0002% mcap100.0% of flowCommon StockSEC:0001145197-26-000184:0
1,100 shares@ US$147.470.0017% mcap13.7% of flowCommon StockSEC:0001145197-26-000172:0
Canonical exit: 19 Nov 2026 (T+90)
244 shares@ US$165.350.0004% mcap100.0% of flowCommon StockSEC:0001145197-26-000165:0
151 shares@ US$152.250.0002% mcap62.1% of flowCommon StockSEC:0001145197-26-000159:0
418 shares@ US$143.270.0005% mcap10.0% of flowCommon StockSEC:0001145197-26-000142:0
418 shares@ US$143.2650.0005% mcap100.0% of flowCommonSEC144:0001959173-26-004306
1,660 shares0Common StockSEC:0001145197-26-000122:0
1,660 shares0Common StockSEC:0001145197-26-000123:0
1,411 shares@ US$148.840.0018% mcap100.0% of flowCommon StockSEC:0001145197-26-000105:0
111 shares@ US$209.84100.0% of flowCommon StockSEC:0001145197-26-000091:0
2,777 shares0Common StockSEC:0001145197-26-000093:0
119 shares@ US$246.613.5% of flowCommon StockSEC:0001145197-26-000073:0
200 shares@ US$246.6112.6% of flowCommon StockSEC:0001145197-26-000074:0
411 shares@ US$246.619.8% of flowCommon StockSEC:0001145197-26-000072:0
207 shares@ US$246.613.9% of flowCommon StockSEC:0001145197-26-000075:0
644 shares@ US$246.614.2% of flowCommon StockSEC:0001145197-26-000071:0
2,140 shares0Common StockSEC:0001145197-26-000065:0
1,044 shares0Common StockSEC:0001145197-26-000064:0
611 shares0Common StockSEC:0001145197-26-000063:0
1,885 shares0Common StockSEC:0001145197-26-000062:0
3,822 shares0Common StockSEC:0001145197-26-000061:0
2,140 shares0Common StockSEC:0001145197-26-000060:0
3,822 shares0Common StockSEC:0001145197-26-000059:0
25 of 295 declarations
About Insulet Corp
Insulet Corp. (NASDAQ: PODD) is a U.S.-based medical technology company headquartered in Acton, Massachusetts, in the United States. For French-speaking investors, it is best understood as a diabetes-focused medtech business rather than a broad healthcare conglomerate. Founded in 2000, Insulet has built its franchise around tubeless insulin delivery and automated insulin management, marketed primarily under the Omnipod brand. The company’s investment case is centered on innovation, recurring patient adoption, and a differentiated product architecture that creates meaningful barriers to entry in a specialized segment of diabetes care. ([investors.insulet.com](https://investors.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx?utm_source=openai))
Insulet’s core business is the Omnipod family of products, especially Omnipod 5, an automated insulin delivery system designed to work with compatible continuous glucose monitoring technology. The product aims to reduce the burden of diabetes management by eliminating tubing, limiting daily injections, and supporting more seamless glucose control. In practical terms, this gives Insulet a strong positioning versus conventional insulin pumps and multiple daily injection regimens, especially for patients and clinicians seeking convenience, discretion, and digital integration. The company also sells related software-enabled features, controllers, and patient support services that help reinforce usage, adherence, and brand loyalty. ([investor.insulet.com](https://investor.insulet.com/news/news-details/2026/Insulet-Redefines-Diabetes-at-CES-with-Liveable-Technology--A-New-Frontier-in-Human-Centered-Connected-Health/default.aspx?utm_source=openai))
Read moreShow less
From a competitive standpoint, Insulet occupies a leading niche in tubeless insulin pump technology. Management has described the company as the global leader in this category, and recent disclosures indicate that Omnipod 5 is available in 19 countries, supporting a growing international footprint beyond its U.S. base. That combination of product differentiation and geographic expansion is important for investors because it suggests a long runway for penetration in both established and newer diabetes markets. ([investors.insulet.com](https://investors.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx?utm_source=openai))
Recent news has been constructive overall. In February 2026, Insulet reported 2025 revenue growth of 31% year over year, reflecting strong commercial momentum in both the U.S. and international markets. In December 2025, the company received U.S. FDA 510(k) clearance for algorithm enhancements to Omnipod 5, including a lower glucose target option and improvements intended to make automated use more seamless. In March 2026, Insulet announced a voluntary medical device correction for certain U.S. Omnipod 5 Pod lots, while stating it did not expect disruption to shipments or new patient starts. Taken together, these developments highlight a business with strong growth, ongoing product innovation, and normal medtech execution risks. ([investors.insulet.com](https://investors.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
